

Bausch Health Announces Filing of Supplement to Proxy Statement

April 22, 2025

Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares

LAVAL, QC, April 22, 2025 – Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) (the “Company” or “Bausch Health”) today announced that it has filed a supplement (the “Proxy Statement Supplement”) to its proxy statement dated April 2, 2025 (the “Proxy Statement”) in respect of the Company’s upcoming annual general meeting of shareholders on May 13, 2025. The Company is updating the Proxy Statement to disclose, in addition to the 34,721,118 common shares reported as being beneficially owned (9.4%), Mr. Carl C. Icahn and his affiliates (collectively, “Icahn”) had entered into cash-settled equity swap agreements covering 90,720,000 of the Company’s common shares (24.6%), with a single maturity date of February 28, 2028. Taken together Icahn now has an economic interest covering approximately 34% of the Company’s outstanding common shares.

On March 12, 2025, the Board of Directors of the Company (the “Board”) adopted a resolution directing the Company’s General Counsel to review the Icahn’s position in equity swaps and certain bonds held by John Paulson, the Chairman of the Board. The General Counsel hired Sidley Austin, LLP (“Sidley”), as independent counsel, to conduct such review. Sidley presented its findings to the Board on April 9, 2025. As part of its review, Sidley sought information regarding Icahn’s swap positions and requested copies of the swap agreements themselves. Icahn refused to provide the copies of the swap agreements, but Icahn informed Sidley that (i) their additional long economic exposure to 90.72 million Company shares through equity swaps was accumulated over more than one hundred trades, executed between May 26, 2021 and September 8, 2023; (ii) the agreements provide for early termination via cash settlement; (iii) the agreements do not confer voting or dispositive power over the referenced shares; and (iv) the agreements do not “allow for” physical settlement.

Regarding Mr. Paulson’s bond position, (i) Mr. Paulson purchased an aggregate of \$50 million Bausch Health bonds prior to rejoining the Board of Bausch Health; (ii) he purchased the bonds in the open market; and (iii) he obtained pre-approval for the bond purchase from the General Counsel of Bausch + Lomb, where he was a Board member. Based on the available facts and the review conducted by Sidley, the Company determined that Mr. Paulson’s bond purchase was not required to be disclosed under Item 404 of Regulation S-K as a related party transaction. Nevertheless, Mr. Paulson has requested that the Company update the Proxy Statement to reflect his bond position and informed the Company that he intends to dispose of his debt securities when the Company’s trading window is open in order to eliminate even the appearance of a conflict of interest and to demonstrate that his interests have always been fully aligned with those of all the Company’s shareholders.

Finally, as previously announced on April 14, 2025, the Company adopted a shareholder rights plan agreement (the “SRP”). The SRP is intended to prevent a person or group from acquiring beneficial ownership of 20% or more of the Company’s outstanding common shares (including by way of a “creeping” take-over bid) without complying with the permitted exemptions under the plan. The SRP protects against such “creeping” take-over bids that may serve to benefit certain

shareholders to the detriment of others. The SRP provides the Board with an opportunity to identify, solicit, develop and negotiate value-enhancing alternatives that benefit all shareholders. Bausch Health is confident that the SRP is in the best interests of the Company and its shareholders.

Except as expressly provided in the Proxy Statement Supplement, the Proxy Statement remains unchanged from the version that was previously filed on SEDAR+ and EDGAR. The Proxy Statement Supplement is available under the Company's profile on the SEDAR+ website at www.sedarplus.ca and the EDGAR website at www.sec.gov/edgar.

About Bausch Health

Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees, and investors.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. Forward-looking statements, by their nature, are based on assumptions and are subject to known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the forward-looking statement will not occur. The forward-looking statements in this press release speak only as of the date hereof and reflect several material factors, expectations and assumptions. Undue reliance should not be placed on any predictions or forward-looking statements as these may be affected by, among other things, changing external events and general uncertainties of the business. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information, or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

Investor Contact:

Garen Sarafian
ir@bauschhealth.com

(877) 281-6642 (toll-free)

Media Contact:

Katie Savastano
corporate.communications@bauschhealth.com

(908) 541-3785

**Investor Inquiries**

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

LEGAL NOTICE**PRIVACY POLICY****EMAIL ALERTS****EMAIL PAGE****RSS FEED**

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights
reserved. MTB.0230.USA.18 V2.0

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

**CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION**